

Supplementary Table

Table S1: Treatment modalities used for ≥G3 toxicities

Overall Toxicities ≥G3	Overall	<65 yrs	65-74 yrs	≥75 yrs	Chi Squared
Total episodes	72	31	27	14	
Treatment					
Non-steroid immunosuppressant	4 (5.6%)	2 (6.5%)	1 (3.7%)	1 (7.1%)	NA
IV Steroid	23 (31.9%)	16 (51.6%)	6 (22.2%)	1 (7.1%)	
Oral Steroid	32 (44.4%)	7 (22.6%)	15 (55.6%)	10 (71.4%)	
Non- immunosuppressant only	11 (15.3%)	4 (12.9%)	5 (18.5%)	2 (14.3%)	
No treatment	2 (2.8%)	2 (6.5%)	0 (0.0%)	0 (0.0%)	
Dermatitis	Overall	<65 yrs	65-74 yrs	≥75 yrs	
Total episodes	3	0	2	1	
Treatment					
IV Steroid	1 (33.3%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	NA
Oral Steroids+ Topical steroid	2 (66.7%)	0 (0.0%)	1 (50.0%)	1 (100.0%)	
Lower GI	Overall	<65 yrs	65-74 yrs	≥75 yrs	
Total episodes	24	13	6	5	
Treatment					
Non-steroid immunosuppressant	2 (8.3%)	1 (7.7%)	1 (16.7%)	0 (0.0%)	NA
IV Steroid	13 (54.2%)	11 (84.6%)	2 (33.3%)	0 (0.0%)	
Oral Steroid	9 (37.5%)	1 (7.7%)	3 (50.0%)	5 (100.0%)	
Endocrine	Overall	<65 yrs	65-74 yrs	≥75 yrs	
Total episodes	11	4	5	2	
Treatment					
Oral Steroid	5 (45.5%)	2 (50.0%)	2 (40.0%)	1 (50.0%)	NA
Non- immunosuppressant only	6 (54.5%)	2 (50.0%)	3 (60.0%)	1 (50.0%)	
Hepatitis	Overall	<65 yrs	65-74 yrs	≥75 yrs	
Total episodes	13	4	5	4	
Treatment					
Non-steroid immunosuppressant	2 (15.4%)	1 (25.0%)	0 (0.0%)	1 (25.0%)	NA
IV Steroid	4 (30.8%)	1 (25.0%)	2 (40.0%)	1 (25.0%)	
Oral Steroid	7 (53.8%)	2 (50.0%)	3 (60.0%)	2 (50.0%)	
Rheumatological	Overall	<65 yrs	65-74 yrs	≥75 yrs	
Total episodes	4	2	2	0	
Treatment					
IV Steroid	1 (25.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	NA
Oral Steroid	3 (75.0%)	1 (50.0%)	2 (100.0%)	0 (0.0%)	
Other Toxicities	Overall	<65 yrs	65-74 yrs	≥75 yrs	
Total episodes	17	8	7	2	
Treatment					
IV Steroid	4 (23.5%)	3 (37.5%)	1 (14.3%)	0 (0.0%)	NA
Oral Steroid	6 (35.3%)	1 (12.5%)	4 (57.1%)	1 (50.0%)	
Other treatment only	5 (29.4%)	2 (25.0%)	2 (28.6%)	1 (50.0%)	
No Treatment	2 (11.8%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	

NA – not enough data for meaningful analysis